PMID: 7536945Jan 1, 1995Paper

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study

Psychopharmacology
G F BusattoR W Kerwin

Abstract

Risperidone and remoxipride are recently introduced atypical antipsychotics, with clinical efficacy comparable to that of classical antipsychotics but lower propensity to induce extrapyramidal side effects (EPS). It is unclear whether these properties relate to weak dopamine D2 receptor blockade in vivo, as has been suggested for the archetypal atypical antipsychotic clozapine. We have used 123I-IBZM single photon emission tomography (SPET) to characterize the patterns of striatal D2 receptor binding in vivo in DSMIII-R-diagnosed schizophrenic and schizo-affective patients treated with either risperidone (n = 6) or remoxipride (n = 4) but predominantly EPS free. These groups were compared to age- and BPRS- matched subjects from a previously reported D2 receptor binding database of patients treated with clozapine (n = 10) and classical antipsychotics (n = 10). Patients on risperidone and remoxipride had high levels of D2 receptor blockade, comparable to those of patients on classical antipsychotics, and significantly greater than those obtained with clozapine-treated patients (risperidone versus clozapine, P < 0.005; remoxipride versus clozapine, P < 0.025). These results suggest high levels of striatal D2 receptor occupancy in ...Continue Reading

References

Jul 1, 1992·Archives of General Psychiatry·H Berenbaum
Mar 1, 1991·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·T BrückeL Deecke
Jan 1, 1991·Schizophrenia Bulletin·J Gerlach
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·S O OgrenK Angeby-Möller
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·L Farde, C von Bahr
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·T LewanderD Morrison
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1989·Psychopharmacology·H Hippius
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Dec 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·G F BusattoR W Kerwin
Jul 6, 1993·European Journal of Pharmacology·N MohellD M Jackson

❮ Previous
Next ❯

Citations

Jul 1, 1995·European Journal of Nuclear Medicine·R W Kerwin, L S Pilowsky
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Apr 1, 1997·Pharmacology, Biochemistry, and Behavior·K M TrimbleD J King
Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle
May 20, 2006·Journal of Sex & Marital Therapy·H KnegteringDurk Wiersma
Apr 1, 1999·Acta Psychiatrica Scandinavica·M BahroJ Strnad
Jan 1, 1997·Journal of Psychopharmacology·G P Reynolds
Mar 1, 2008·Journal of Psychopharmacology·A M CatafauUNKNOWN Barcelona Clinical Imaging in Psychiatry Group
Jan 1, 1997·Journal of Psychopharmacology·G F Busatto, R W Kerwin
May 5, 2000·The Cochrane Database of Systematic Reviews·A TuunainenS M Gilbody
Jan 25, 2003·Journal of Clinical Psychopharmacology·Rodrigo A BressanLyn S Pilowsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here